Cart
sales@molnova.com
Vorolanib
CAS No. 1013920-15-4
Vorolanib( CM082,X-82 )
Catalog No. M21932 CAS No. 1013920-15-4
Vorolanib is an orally active VEGFR/PDGFR dual inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 250 | In Stock |
|
| 2MG | 145 | In Stock |
|
| 5MG | 227 | In Stock |
|
| 10MG | 359 | In Stock |
|
| 25MG | 616 | In Stock |
|
| 50MG | 870 | In Stock |
|
| 100MG | 1181 | In Stock |
|
| 200MG | 1572 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVorolanib
-
NoteResearch use only, not for human use.
-
Brief DescriptionVorolanib is an orally active VEGFR/PDGFR dual inhibitor.
-
DescriptionVorolanib is an orally active VEGFR/PDGFR dual inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsCM082,X-82
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR|PDGFR
-
Research AreaUrinary system/Cancer
-
IndicationRenal Cell Cancer Metastatic
Chemical Information
-
CAS Number1013920-15-4
-
Formula Weight439.48
-
Molecular FormulaC23H26FN5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:22 mg/ml (50.06 mM; Need ultrasonic)
-
SMILESCN(C)C(=O)N1CC[C@@H](C1)NC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bendell JC, et al. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. Oncologist. 2019 Apr;24(4):455-e121.
molnova catalog
related products
-
UNC0064-12 hydrochlo...
UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1.
-
AMPK-IN-3
AMPK-IN-3 is a novel, selective and potent AMPK inhibitor with inhibitory effects on AMPK (α2), AMPK (α1) and KDR, with IC50 values of 60.7, 107 and 3820 nM, respectively.AMPK-IN-3 showed anticancer activity in K562 cells.
-
Vatalanib free base
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
